Immune Checkpoint Inhibitor Adverse Event Management: A Comprehensive Clinical Guideline

Evidence-based guideline for recognition, grading, and management of immune-related adverse events (irAEs) across all organ systems in patients receiving checkpoint inhibitor immunotherapy.

5 articles • Updated Mar 2026

Immune Checkpoint Inhibitor Adverse Event Management — Part 5: Hematologic, Ophthalmologic irAEs, Special Populations, and Rechallenge

Management of immune-mediated hematologic toxicities, ophthalmologic irAEs, combination immunotherapy toxicity profiles, rechallenge criteria, preexisting autoimmune disease, special populations, multidisciplinary triggers, and patient education.

guidelines•Mar 2026•guidelines

Immune Checkpoint Inhibitor Adverse Event Management — Part 4: Cardiac, Neurologic, Renal, and Musculoskeletal irAEs

Grade-based management of immune-mediated myocarditis, pericarditis, neurologic toxicities (myasthenia gravis, encephalitis, Guillain-Barre, neuropathy), nephritis, inflammatory arthritis, and myositis.

guidelines•Mar 2026•guidelines

Immune Checkpoint Inhibitor Adverse Event Management — Part 3: Endocrine and Pulmonary irAEs

Grade-based management of immune-mediated endocrine toxicities (thyroid disorders, adrenal insufficiency, hypophysitis, type 1 diabetes) and pneumonitis including workup, corticosteroid protocols, hormone replacement, and immunosuppressive escalation.

guidelines•Mar 2026•guidelines

Immune Checkpoint Inhibitor Adverse Event Management — Part 2: Dermatologic, Gastrointestinal, and Hepatic irAEs

Grade-based management of immune-mediated dermatologic toxicities (rash, pruritus, bullous pemphigoid, SJS/TEN), colitis/diarrhea, and hepatitis including workup, corticosteroid protocols, and immunosuppressive escalation.

guidelines•Mar 2026•guidelines

Immune Checkpoint Inhibitor Adverse Event Management — Part 1: Overview of Checkpoint Inhibitors and General Principles of irAE Management

Classes of immune checkpoint inhibitors, mechanism and epidemiology of irAEs, CTCAE grading, general management framework, corticosteroid protocols, immunosuppressive escalation, and infusion reactions.

guidelines•Mar 2026•guidelines